triple negative breast neoplasms
Showing 1 - 25 of 39
Triple Negative Breast Tumors Trial (Xiaopi granules, Xiaopi decoction, Placebo)
Not yet recruiting
- Triple Negative Breast Neoplasms
- Xiaopi granules
- +2 more
- (no location specified)
Nov 22, 2023
Triple Negative Breast Tumors Trial in Paris (Atezolizumab + RP1)
Not yet recruiting
- Triple Negative Breast Neoplasms
- Atezolizumab + RP1
-
Paris, FranceInstitut Curie
Oct 2, 2023
Breast Cancer, Inflammatory Breast Cancer Stage IV, Inflammatory Breast Tumors Trial in Knoxville (Self-Administered Hypnosis,
Recruiting
- Breast Cancer
- +4 more
- Self-Administered Hypnosis
- Self-Administered White Noise Hypnosis
-
Knoxville, TennesseeUniversity of Tennessee Knoxville
Sep 26, 2023
Triple Negative Breast Tumors Trial (Pembrolizumab injection, Capecitabine tablets, Local radiotherapy)
Not yet recruiting
- Triple Negative Breast Neoplasms
- Pembrolizumab injection
- +2 more
- (no location specified)
Jul 25, 2023
Uterine Cervical Tumors, Endometrial Tumors, Squamous Cell Carcinoma of Head and Neck Trial in Worldwide
Recruiting
- Uterine Cervical Neoplasms
- +10 more
- Pembrolizumab/Vibostolimab Co-Formulation
- +11 more
-
Anchorage, Alaska
- +65 more
Jan 27, 2023
Triple Negative Breast Tumors Trial in Worldwide (alpelisib, , nab-paclitaxel)
Active, not recruiting
- Triple Negative Breast Neoplasms
- alpelisib
- +2 more
-
Los Alamitos, California
- +154 more
Jan 12, 2023
Triple Negative Breast Tumors Trial in Worldwide (Atezolizumab, Placebo, Gemcitabine)
Recruiting
- Triple Negative Breast Neoplasms
- Atezolizumab
- +4 more
-
Fort Myers, Florida
- +165 more
Jan 12, 2023
Triple Negative Breast Tumors Trial in Worldwide (ladiratuzumab vedotin, Pembrolizumab)
Recruiting
- Triple Negative Breast Neoplasms
- ladiratuzumab vedotin
- Pembrolizumab
-
Birmingham, Alabama
- +49 more
Jan 4, 2023
Triple Negative Breast Tumors Trial in Worldwide (Pembrolizumab, Olaparib, Carboplatin)
Active, not recruiting
- Triple Negative Breast Neoplasms
- Pembrolizumab
- +3 more
-
Monterey, California
- +121 more
Oct 10, 2022
Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Tumors Trial in Worldwide (AZD8701, Durvalumab)
Recruiting
- Clear Cell Renal Cell Cancer
- +8 more
- AZD8701
- Durvalumab
-
La Jolla, California
- +22 more
Aug 12, 2022
Triple Negative Breast Tumors, Triple Negative Breast Cancer, Breast Tumors Trial (Pembrolizumab, Paclitaxel, Carboplatin)
Not yet recruiting
- Triple Negative Breast Neoplasms
- +7 more
- Pembrolizumab
- +4 more
- (no location specified)
Aug 1, 2022
Breast Cancer, Triple Negative Breast Tumors Trial in France (Nivolumab, Ipilimumab, Capecitabine)
Active, not recruiting
- Breast Cancer
- Triple Negative Breast Neoplasms
- Nivolumab
- +2 more
-
Angers, France
- +16 more
Jul 21, 2022
Triple Negative Breast Tumors Trial in Worldwide (Pembrolizumab, Carboplatin, Paclitaxel)
Active, not recruiting
- Triple Negative Breast Neoplasms
- Pembrolizumab
- +7 more
-
Scottsdale, Arizona
- +192 more
Jul 8, 2022
Precision Neoadjuvant Triple-negative Breast Cancer Treatment
Recruiting
- Triple Negative Breast Cancer
- Triple Negative Breast Neoplasms
- Core needle biopsy
-
London, United KingdomBarts Health NHS Trust
Jun 22, 2022
Breast Tumors, Triple Negative Breast Tumors Trial in Chicago, Madison (drug, procedure, other)
Terminated
- Breast Neoplasms
- Triple Negative Breast Neoplasms
- Dasatinib
- +2 more
-
Chicago, Illinois
- +1 more
Jun 2, 2022
Triple Negative Breast Tumors Trial in Italy, United Kingdom (MSB0010718C)
Active, not recruiting
- Triple Negative Breast Neoplasms
-
Bergamo, BG, Italy
- +71 more
Mar 31, 2022
NSCLC, Triple Negative Breast Tumors, Squamous Cell Carcinoma of Head and Neck Trial in United States (Pembrolizumab, TAK-676,
Recruiting
- Carcinoma, Non-Small-Cell Lung
- +2 more
- Pembrolizumab
- +2 more
-
West Hollywood, California
- +5 more
Mar 17, 2022
Triple Negative Breast Tumors Trial in San Francisco, Chicago (350 mg leronlimab, 525 mg leronlimab, 700 mg leronlimab)
Active, not recruiting
- Triple Negative Breast Neoplasms
- 350 mg leronlimab
- +4 more
-
San Francisco, California
- +1 more
Mar 18, 2022
Triple Negative Breast Cancer, Triple Negative Breast Tumors, TNBC - Triple-Negative Breast Cancer Trial in Saint Louis (drug,
Active, not recruiting
- Triple Negative Breast Cancer
- +3 more
- Durvalumab
- +3 more
-
Saint Louis, MissouriWashington University School of Medicine
Mar 14, 2022
Triple Negative Breast Cancer, Triple Negative Breast Tumors, Triple-Negative Breast Cancer Trial (Personalized synthetic long
Withdrawn
- Triple Negative Breast Cancer
- +2 more
- Personalized synthetic long peptide vaccine (Poly ICLC)
- Poly ICLC
- (no location specified)
Mar 9, 2022